{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:09Z","timestamp":1777934649051,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of certain chemotherapy agents is associated with the development of a condition called \u201cchemotherapy-associated neutropenic enterocolitis\u201d (CANE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the risk of CANE associated with the use of each antineoplastic agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The FDA FAERS database of spontaneous adverse reactions was searched for the occurrence of the MedDRA preferred term \u201cneutropenic colitis.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The search resulted in 1134 records of patients (535 [47.3%] females, 479 [42.2%] males, sex not specified in 120 [10.6%]) with neutropenic colitis receiving immunosuppressive chemotherapy. The mean age of patients was 47 (SD 22). 22 antineoplastic agents were found to have a strong association (reported odds ratio [ROR]\u2009&gt;\u2009100) with the occurrence of CANE; 9 had ROR &lt; 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Drug databases have several limitations in providing updated information about newly approved pharmaceutical adverse events. Signal detection is a diagnostic method recognized as practical in pharmacovigilance. It may be utilized in the FDA's adverse event reporting database and has demonstrated a reasonable predictive performance in signaling adverse events. Our study emphasized the substantial knowledge gap between what we know about the potential risk of CANE caused by antineoplastic agents and the reports of the FDA on their new approved products.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241238195","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T08:40:48Z","timestamp":1710319248000},"page":"381-387","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Antineoplastic agents associated with neutropenic enterocolitis in patients with malignancy: A quantitative safety signal analysis"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9173-2853","authenticated-orcid":false,"given":"Ali","family":"Amanati","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran"},{"name":"Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robbert","family":"Van Manen","sequence":"additional","affiliation":[{"name":"Oracle Health Sciences, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarvin","family":"Sajedianfard","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafez","family":"Shojaadini","sequence":"additional","affiliation":[{"name":"Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohadese","family":"Boroughani","sequence":"additional","affiliation":[{"name":"Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Molavi Vardanjani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran"},{"name":"Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0766-2"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-006-0055-z"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis998"},{"key":"e_1_3_3_5_2","first-page":"718","article-title":"Chemotherapy-induced neutropenic necrotizing enterocolitis: a review","volume":"62","author":"Mehdi I","year":"2012","unstructured":"Mehdi I, Bahrain B. Chemotherapy-induced neutropenic necrotizing enterocolitis: a review. J Pak Med Assoc 2012; 62: 718.","journal-title":"J Pak Med Assoc"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100944"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.124537"},{"key":"e_1_3_3_8_2","first-page":"35","article-title":"Reporting adverse drug events","author":"Mayer MH","year":"2010","unstructured":"Mayer MH, Dowsett SA, Brahmavar K, et al. Reporting adverse drug events. US Pharm 2010; 35\u201336.","journal-title":"US Pharm"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2003.20130.x"},{"key":"e_1_3_3_10_2","first-page":"31","article-title":"FDA adverse event reporting system (FAERS) public dashboard","author":"Food U","year":"2018","unstructured":"Food U, Administration D. FDA adverse event reporting system (FAERS) public dashboard. Data March 2018; 31\u201332.","journal-title":"Data March"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528110-00002"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225060-00001"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3468(99)90566-3"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102193"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxres\/tfab026"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.09.011"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199512000-00007"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2018.05.011"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4746"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1549221"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1776255"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.590.590"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1217991"},{"key":"e_1_3_3_24_2","first-page":"1","volume-title":"StatPearls [Internet]","author":"Arora RD","year":"2021","unstructured":"Arora RD, Menezes RG. Vinca alkaloid toxicity. In: StatPearls [Internet]. StatPearls Publishing, 2021, p 1\u20135."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01309-0"},{"key":"e_1_3_3_26_2","first-page":"2103","article-title":"Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer","volume":"9","author":"Xuhong JC","year":"2019","unstructured":"Xuhong JC, Qi XW, Zhang Y, et al. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res 2019; 9: 2103.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860201)57:3<616::AID-CNCR2820570337>3.0.CO;2-4"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920101)69:1<17::AID-CNCR2820690106>3.0.CO;2-X"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200006000-00021"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21134"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-002-0079-y"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1973.01350190029008"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i1.42"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-006-0092-y"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(86)90547-7"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900215)65:4<1041::AID-CNCR2820650433>3.0.CO;2-A"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp035"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)73080-4"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241238195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241238195","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241238195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:38Z","timestamp":1777688978000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241238195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/10781552241238195"],"URL":"https:\/\/doi.org\/10.1177\/10781552241238195","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]}}}